INmune Bio files investor presentation on INKmune phase I/II in prostate cancer - no specific data disclosed

Inmune Bio, Inc.

Preliminary phase I/II results for INKmune in metastatic castration-resistant prostate cancer highlighted in new investor deck.
No specific efficacy or safety data provided in the 8-K excerpt; full slide content not available.
Presentation focuses on in vivo activation of memory-like NK cells (mlNK) using INKmune.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.